跳至主要内容
临床试验/NCT04032925
NCT04032925终止2 期

Understanding the Effects of Pressure-controlled Intermittent Coronary Sinus Occlusion Assisted Percutaneous Coronary Intervention on Coronary Physiology and Left Ventricular Performance

Oxford University Hospitals NHS Trust2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2021年8月3日最近更新:
适应症

试验速览

阶段
2 期
状态
终止
入组人数
2
试验地点
2
主要终点
Stroke work

研究概览

简要总结

The PICSO ViPER study is a prospective single centre cohort study of the use of PICSO in patients presenting acute myocardial infarction and impaired function of the left ventricle and candidate to angioplasty the left anterior descending (LAD) coronary artery.

The percutaneous coronary intervention (PCI) procedure will be undertaken in a standard fashion, in accordance with the Oxford University Hospitals NHS Trust (OUHT) departmental guidelines for PCI, and includes the use of pressure wire measurements before and after stent deployment. PICSO treatment will be added on top of the conventional treatment.

The protocol will constitute of 5 main stages (that will all be performed during index angioplasty procedure). The protocol is complete at the end of the angioplasty procedure, and the patient will exit the study at this point. The five stages of the protocol are described below (for details see "Detailed Description"):

  • Baseline
  • PICSO treatment during pre-dilation
  • Stenting with PICSO support
  • Post-stent Physiology
  • PICSO treatment during post-dilation

详细描述

In detail, the five stages of the PICSO VIPER study include:

Stage 1: Baseline

  • Diagnostic angiography will be performed in the standard manner using appropriate catheters.
  • Pre-stenting coronary physiology parameters, namely fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) will be measured, using a pressure wire, as used for routine clinical measurements in patients undergoing PCI.
  • Via a separate arterial access, a conductance catheter will be inserted retrogradely in the left ventricle for baseline measurements of cardiac pump function .
  • Baseline blood samples will be withdrawn from the CS (via PICSO balloon) and ascending aorta (via coronary guiding catheter used for revascularization)

Stage 2: PICSO treatment during pre-dilation

  • The PICSO device will be deployed as already previously described in the literature.
  • Pre-dilation will be performed using an angioplasty balloon at a size determined by the operator, as per standard clinical practice. Balloon will be maintained inflated for a minimum of 1 minute to a maximum of 2 minutes if well tolerated by the patient.
  • Balloon inflation will be performed once with the PICSO device activated and once with PICSO device in standby. The order of this will be determined by randomisation via Sequentially Numbered Opaque Sealed Envelopes.
  • During each balloon inflation measurements of coronary and cardiac function will be performed and blood samples will be collected exactly as in stage 1.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Admission with NSTEMI and considered for coronary angiogram for a view for PCI
  • Echocardiographic evidence of at least mild left ventricular systolic impairment (Ejection Fraction < 50%) or regional wall motion abnormalities in LAD territory
  • Angiographically proven stenosis of the LAD treated with PCI

排除标准

  • Patient referred for surgical revascularization or considered for medical management of coronary disease
  • Planned revascularization by mean of balloon angioplasty without stenting
  • Patients in whom safety or clinical concerns preclude participation. These would include:
  • Significant left main stem disease
  • Cardiogenic shock and/or haemodynamic instability at the time of enrolment/screening
  • Recent PCI or admission with acute coronary syndrome in the previous 3 months before screening/enrolment
  • Known anaemia (Hb < 90 g/L)
  • Pregnant or breast-feeding females
  • History of stroke, TIA or reversible ischaemic neurological disease within last 6 months
  • Known severe renal failure (eGFR < 30 ml/min/1.73m2) or history of dialysis or renal transplant
  • Previous coronary bypass artery grafting
  • Previous PCI to LAD
  • Known severe valvular abnormalities
  • Use of warfarin
  • Presence of pacemaker electrode or medical device in the coronary sinus
  • History of inability or, in the opinion of the investigator, anticipated inability to tolerate pharmacologic stress testing (e.g. second- or third-degree AV block without a cardiac pacemaker, severe asthma, resting systolic blood pressure <90mmHg, unstable coronary disease, use of medications which may interfere with the test).
  • Unwilling, or unable, to give informed consent.

结局指标

主要结局

Stroke work

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

End diastolic pressure volume relationship (EDPVR)

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

Maximum dp/dt

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

Cardiac Efficiency

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

Pressure-Volume Area (PVA)

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

Minimum dp/dt

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

End-systolic pressure volume relationship (ESPVR)

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

Tau

时间窗: At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment)

Parameter of ventricular physiology and performance

次要结局

  • Transcoronary oxygen content(At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment))
  • Transcoronary gradient of lactates levels(At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment))
  • Transcoronary microRNA gradient(At completion of index percutaneous coronary intervention (on average 90 minutes post enrolment))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Giovanni Luigi De Maria

Primary Investigator

Oxford University Hospitals NHS Trust

研究点 (2)

Loading locations...

相似试验

The Pressure-controlled Intermittent Coronary Sinus... | 临床试验